| Year |
Citation |
Score |
| 1999 |
Han ES, Zhang JT. Membrane orientation of carboxyl-terminal half P-glycoprotein: Topogenesis of transmembrane segments European Journal of Cell Biology. 78: 624-631. PMID 10535304 DOI: 10.1016/S0171-9335(99)80047-8 |
0.344 |
|
| 1998 |
Han ES, Zhang JT. Mechanism involved in generating the carboxyl-terminal half topology of P-glycoprotein Biochemistry. 37: 11996-12004. PMID 9718325 DOI: 10.1021/Bi980702P |
0.391 |
|
| 1998 |
Zhang JT, Chen M, Han E, Wang C. Dissection of de novo membrane insertion activities of internal transmembrane segments of ATP-binding-cassette transporters: toward understanding topological rules for membrane assembly of polytopic membrane proteins. Molecular Biology of the Cell. 9: 853-63. PMID 9529383 DOI: 10.1091/Mbc.9.4.853 |
0.408 |
|
| 1997 |
Wang C, Chen M, Han E, Zhang JT. Role of ribosomes in reinitiation of membrane insertion of internal transmembrane segments in a polytopic membrane protein. Biochemistry. 36: 11437-43. PMID 9298963 DOI: 10.1021/Bi970041G |
0.346 |
|
| 1996 |
Han ES, Vanoye CG, Altenberg GA, Reuss L. P-glycoprotein-associated chloride currents revealed by specific block by an anti-P-glycoprotein antibody American Journal of Physiology - Cell Physiology. 270. PMID 8967437 DOI: 10.1152/Ajpcell.1996.270.5.C1370 |
0.318 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2015 |
Wang Y, Han E, Xing Q, Yan J, Arrington A, Wang C, Tully D, Kowolik CM, Lu DM, Frankel PH, Zhai J, Wen W, Horne D, Yip ML, Yim JH. Baicalein upregulates DDIT4 expression which mediates mTOR inhibition and growth inhibition in cancer cells. Cancer Letters. 358: 170-9. PMID 25543165 DOI: 10.1016/J.Canlet.2014.12.033 |
0.266 |
|
| 2018 |
Wen W, Lowe G, Roberts CM, Finlay J, Han ES, Glackin CA, Dellinger TH. Pterostilbene Suppresses Ovarian Cancer Growth via Induction of Apoptosis and Blockade of Cell Cycle Progression Involving Inhibition of the STAT3 Pathway. International Journal of Molecular Sciences. 19. PMID 29986501 DOI: 10.3390/ijms19071983 |
0.257 |
|
| 2015 |
Cristea MC, Synold TW, Frankel PH, Rivkin SE, Lim D, Chung VM, Chao J, Wakabayashi MT, Paz IB, Han ES, Lin P, Leong LA, Hakim A, Carroll MI, Openshaw H, et al. Pharmacologic advantage (PA) of intraperitoneal (IP) nab-paclitaxel in patients with advanced malignancies primarily confined to the peritoneal cavity. Journal of Clinical Oncology. 33: 2553-2553. DOI: 10.1200/Jco.2015.33.15_Suppl.2553 |
0.246 |
|
| 2002 |
Luh JY, Han ES, Simmons JR, Whitehead RP. Poorly differentiated colon carcinoma with neuroendocrine features presenting with hypercalcemia and cutaneous metastases: case report and review of the literature. American Journal of Clinical Oncology. 25: 160-3. PMID 11943894 DOI: 10.1097/00000421-200204000-00011 |
0.245 |
|
| 2019 |
Yuan Y, Wen W, Yost SE, Xing Q, Yan J, Han ES, Mortimer J, Yim JH. Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer. Scientific Reports. 9: 7509. PMID 31101835 DOI: 10.1038/s41598-019-43429-7 |
0.238 |
|
| 2016 |
Zhang K, Han ES, Dellinger TH, Lu J, Nam S, Anderson RA, Yim JH, Wen W. Cinnamon extract reduces VEGF expression via suppressing HIF-1α gene expression and inhibits tumor growth in mice. Molecular Carcinogenesis. PMID 27253180 DOI: 10.1002/mc.22506 |
0.223 |
|
| 2013 |
Dellinger TH, Warden C, Han ES, Wakabayashi MT. L1-CAM as a predictor of survival in endometrial cancer: An analysis of The Cancer Genome Atlas (TCGA). Journal of Clinical Oncology. 31: 5599-5599. DOI: 10.1200/JCO.2013.31.15_SUPPL.5599 |
0.218 |
|
| 2007 |
Han ES, Monk BJ. Bevacizumab in the treatment of ovarian cancer Expert Review of Anticancer Therapy. 7: 1339-1345. PMID 17944559 DOI: 10.1586/14737140.7.10.1339 |
0.189 |
|
| 2013 |
Luu TH, Xing Q, Yan J, Tully D, Han ES, Yip R, Yim JH. Effect of eribulin on cell growth and PI3K pathway activity with and without RAD001 in triple-negative and HER2-expressing breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 173. PMID 28136613 DOI: 10.1200/jco.2013.31.26_suppl.173 |
0.187 |
|
| 2016 |
Han E, Xing Q, Yan J, Wen W, Dellinger T, Wakabayashi M, Yim J. Preclinical data supporting the flavone baicalein as a novel mTOR inhibitor with potent activity against endometrial cancer cells Gynecologic Oncology. 141: 46. DOI: 10.1016/J.YGYNO.2016.04.140 |
0.179 |
|
| 2018 |
Han ES, Wen W, Dellinger TH, Wu J, Lu SA, Jove R, Yim JH. Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer. Oncotarget. 9: 24304-24319. PMID 29849942 DOI: 10.18632/oncotarget.24368 |
0.177 |
|
| 2007 |
Randall-Whitis L, Monk BJ, Han ES, Darcy K, Burger RA, Liao S, Peters WA, Stock RJ, Fruehauf JP. Markers of angiogenesis in cervical cancer: A Gynecologic Oncology Group study Journal of Clinical Oncology. 25: 5536-5536. DOI: 10.1200/Jco.2007.25.18_Suppl.5536 |
0.174 |
|
| 2021 |
Nath A, Cosgrove PA, Mirsafian H, Christie EL, Pflieger L, Copeland B, Majumdar S, Cristea MC, Han ES, Lee SJ, Wang EW, Fereday S, Traficante N, Salgia R, Werner T, et al. Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer. Nature Communications. 12: 3039. PMID 34031395 DOI: 10.1038/s41467-021-23171-3 |
0.173 |
|
| 2019 |
Wen W, Han ES, Dellinger TH, Wu J, Guo Y, Buettner R, Horne DA, Jove R, Yim JH. Increasing Antitumor Activity of JAK Inhibitor by Simultaneous Blocking Multiple Survival Signaling Pathways in Human Ovarian Cancer. Translational Oncology. 12: 1015-1025. PMID 31141756 DOI: 10.1016/J.Tranon.2019.05.003 |
0.172 |
|
| 2020 |
Wen W, Han ES, Dellinger TH, Lu LX, Wu J, Jove R, Yim JH. Synergistic Anti-Tumor Activity by Targeting Multiple Signaling Pathways in Ovarian Cancer. Cancers. 12. PMID 32927828 DOI: 10.3390/cancers12092586 |
0.17 |
|
| 2017 |
Wen W, Lowe G, Roberts CM, Finlay J, Han ES, Glackin CA, Dellinger TH. Pterostilbene, a natural phenolic compound, synergizes the antineoplastic effects of megestrol acetate in endometrial cancer. Scientific Reports. 7: 12754. PMID 28986550 DOI: 10.1038/s41598-017-12922-2 |
0.169 |
|
| 2010 |
Parmakhtiar B, Han E, Fruehauf JP. Abstract 3511: Modulation of HIF-1α by topotecan is related to topoisomerase I-associated with HIF-1α mRNA in ovarian cancer Cancer Research. 70: 3511-3511. DOI: 10.1158/1538-7445.Am10-3511 |
0.165 |
|
| 2014 |
Wen W, Liang W, Wu J, Kowolik CM, Buettner R, Scuto A, Hsieh MY, Hong H, Brown CE, Forman SJ, Horne D, Morgan R, Wakabayashi M, Dellinger TH, Han ES, et al. Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer. Molecular Cancer Therapeutics. 13: 3037-48. PMID 25319391 DOI: 10.1158/1535-7163.Mct-14-0077 |
0.158 |
|
| 2013 |
Dellinger T, Warden C, Han E, Wakabayashi M. Wnt pathway gene expression and association with clinicopathologic characteristics in endometrial cancer – An analysis of The Cancer Genome Atlas (TCGA) Gynecologic Oncology. 130: e89. DOI: 10.1016/J.YGYNO.2013.04.267 |
0.149 |
|
| 2020 |
Cristea M, Frankel P, Synold T, Stewart D, Wang E, Jung A, Wilczynski S, Tran M, Konecny G, Eng M, Kilpatrick L, Chen Y, Glaser S, Han E, Dellinger T, et al. 863P A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in pts with selected FRα -positive solid tumours: Results in the endometrial cancer (EC) cohort Annals of Oncology. 31: S639. DOI: 10.1016/j.annonc.2020.08.1002 |
0.148 |
|
| 2019 |
Wen W, Marcinkowski E, Luyimbazi D, Luu T, Xing Q, Yan J, Wang Y, Wu J, Guo Y, Tully D, Han ES, Yost SE, Yuan Y, Yim JH. Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer. Cells. 8. PMID 31480338 DOI: 10.3390/cells8091010 |
0.146 |
|
| 2021 |
Mooney R, Abidi W, Batalla-Covello J, Ngai HW, Hyde C, Machado D, Abdul-Majid A, Kang Y, Hammad M, Flores L, Copeland G, Dellinger T, Han E, Berlin J, Aboody KS. Allogeneic human neural stem cells for improved therapeutic delivery to peritoneal ovarian cancer. Stem Cell Research & Therapy. 12: 205. PMID 33761999 DOI: 10.1186/s13287-021-02226-8 |
0.145 |
|
| 2013 |
Mooney R, Gilchrist M, Weng Y, Annala A, Bhojane S, Garcia E, Roma L, Schnarr K, Dellinger T, Han E, Karen AS, Berlin JM. Abstract A41: Harnessing neural stem cell tumor tropism for targeted nanoparticle delivery: Potential for ovarian cancer therapy Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-A41 |
0.141 |
|
| 2009 |
Han ES, Lin P, Wakabayashi M. Current status on biologic therapies in the treatment of epithelial ovarian cancer. Current Treatment Options in Oncology. 10: 54-66. PMID 19381822 DOI: 10.1007/s11864-009-0100-x |
0.14 |
|
| 2012 |
Twu C, Han ES. Clinical utility of targeted treatments in the management of epithelial ovarian cancer. Biologics : Targets & Therapy. 6: 233-44. PMID 22904615 DOI: 10.2147/BTT.S29356 |
0.139 |
|
| 2007 |
Han ES, Burger RA, Randall-Whitis L, Parmakhtiar B, Darcy K, Sill M, Connelly P, Monk BJ, Fruehauf JP. Relationship of angiogenesis biomarkers and clinical response to bevacizumab (Bev) in persistent or recurrent epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC) patients treated in a Phase II Gynecologic Oncology Group study Journal of Clinical Oncology. 25: 21021-21021. DOI: 10.1200/Jco.2007.25.18_Suppl.21021 |
0.139 |
|
| 2010 |
Cristea M, Han E, Salmon L, Morgan RJ. Practical considerations in ovarian cancer chemotherapy. Therapeutic Advances in Medical Oncology. 2: 175-87. PMID 21789133 DOI: 10.1177/1758834010361333 |
0.135 |
|
| 2010 |
Han ES, Burger RA, Darcy KM, Sill MW, Randall LM, Chase D, Parmakhtiar B, Monk BJ, Greer BE, Connelly P, Degeest K, Fruehauf JP. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecologic Oncology. 119: 484-90. PMID 20870280 DOI: 10.1016/J.Ygyno.2010.08.016 |
0.132 |
|
| 2014 |
Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, Dupont N, Eifel PJ, Fader AN, Fisher CM, Gaffney DK, George S, ... Han E, et al. Uterine neoplasms, version 1.2014. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 248-80. PMID 24586086 |
0.131 |
|
| 2023 |
Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, Campos SM, Chino J, Chon HS, Chu C, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, ... ... Han E, et al. Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 21: 181-209. PMID 36791750 DOI: 10.6004/jnccn.2023.0006 |
0.128 |
|
| 2019 |
Cristea MC, Frankel PH, Synold TW, Mortimer JE, Stewart DB, Wang EW, Jung A, Wilczynski SP, Konecny GE, Parungao D, Eng M, Kilpatrick L, Chen Y, Glaser S, Han ES, et al. A phase I study of mirvetuximab soravtansine (IMGN853) and gemcitabine (G) in patients with FOLR1-positive recurrent epithelial ovarian (EOC), endometrial cancer (EC), or triple-negative breast cancer (TNBC). Journal of Clinical Oncology. 37: 3009-3009. DOI: 10.1200/JCO.2019.37.15_SUPPL.3009 |
0.127 |
|
| 2015 |
Wen W, Wu J, Liu L, Tian Y, Buettner R, Hsieh MY, Horne D, Dellinger TH, Han ES, Jove R, Yim JH. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer. Molecular Cancer. 14: 100. PMID 25928246 DOI: 10.1186/S12943-015-0366-5 |
0.125 |
|
| 2016 |
Dellinger TH, Smith DD, Ouyang C, Warden CD, Williams JC, Han ES. L1CAM is an independent predictor of poor survival in endometrial cancer - An analysis of The Cancer Genome Atlas (TCGA). Gynecologic Oncology. PMID 26861585 DOI: 10.1016/J.Ygyno.2016.02.003 |
0.119 |
|
| 2018 |
Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, ... ... Han E, et al. Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 16: 170-199. PMID 29439178 DOI: 10.6004/Jnccn.2018.0006 |
0.118 |
|
| 2015 |
Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, et al. Cervical Cancer, Version 2.2015. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 395-404; quiz 404. PMID 25870376 DOI: 10.6004/Jnccn.2015.0055 |
0.115 |
|
| 2006 |
Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer Gynecologic Oncology. 102: 140-144. PMID 16790264 DOI: 10.1016/j.ygyno.2006.05.006 |
0.115 |
|
| 2011 |
Han ES, Wakabayashi M. Indications for minimally invasive surgery for ovarian cancer Jnccn Journal of the National Comprehensive Cancer Network. 9: 126-132. PMID 21233249 |
0.114 |
|
| 2023 |
Senguttuvan RN, Santiago NL, Han ES, Lee B, Lee S, Lin WC, Kebria M, Hakim A, Lin JF, Wakabayashi MT, Ruel N, Tinsley R, Eng M, Stewart DB, Wang EW, et al. Impact of Sodium Thiosulfate on Prevention of Nephrotoxicities in HIPEC: An Ancillary Evaluation of Cisplatin-Induced Toxicities in Ovarian Cancer. Annals of Surgical Oncology. PMID 37710139 DOI: 10.1245/s10434-023-14216-6 |
0.114 |
|
| 2017 |
Dellinger TH, Hakim AA, Lee SJ, Wakabayashi MT, Morgan RJ, Han ES. Surgical Management of Vulvar Cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 15: 121-128. PMID 28040722 |
0.114 |
|
| 2006 |
Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA. Salvage Bevacizumab (rhuMAB VEGF)-Based Therapy After Multiple Prior Cytotoxic Regimens in Advanced Refractory Epithelial Ovarian Cancer Obstetrical & Gynecological Survey. 61: 711-712. DOI: 10.1097/01.OGX.0000243927.32269.8B |
0.114 |
|
| 2021 |
Woo Y, Chaurasiya S, O'Leary M, Han E, Fong Y. Fluorescent imaging for cancer therapy and cancer gene therapy. Molecular Therapy Oncolytics. 23: 231-238. PMID 34729398 DOI: 10.1016/j.omto.2021.06.007 |
0.113 |
|
| 2017 |
Koh WJ, Greer BE, Abu-Rustum NR, Campos SM, Cho KR, Chon HS, Chu C, Cohn D, Crispens MA, Dizon DS, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, ... Han E, et al. Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 15: 92-120. PMID 28040721 |
0.108 |
|
| 2013 |
Han ES, Wakabayashi M, Leong L. Angiogenesis inhibitors in the treatment of epithelial ovarian cancer Current Treatment Options in Oncology. 14: 22-33. PMID 23288484 DOI: 10.1007/s11864-012-0220-6 |
0.107 |
|
| 2021 |
Thornblade LW, Han E, Fong Y. Colorectal cancer ovarian metastases. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 34083378 DOI: 10.1136/ijgc-2020-002328 |
0.105 |
|
| 2017 |
Cao P, Mooney R, Tirughana R, Abidi W, Aramburo S, Flores L, Gilchrist M, Nwokafor U, Haber T, Tiet P, Annala AJ, Han E, Dellinger T, Aboody KS, Berlin JM. Intraperitoneal Administration of Neural Stem Cell-Nanoparticle Conjugates Targets Chemotherapy to Ovarian Tumors. Bioconjugate Chemistry. PMID 28453256 DOI: 10.1021/Acs.Bioconjchem.7B00237 |
0.104 |
|
| 2008 |
Han ES, Burger R, Darcy KM, Sill MW, Greer BE, Sorosky JI, Fruehauf JP. Relationship between angiogenic markers and clinicopathologic factors/outcome in GOG-170D, a phase II trial of bevacizumab (Bev) in recurrent or persistent epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5577. PMID 27950426 DOI: 10.1200/Jco.2008.26.15_Suppl.5577 |
0.104 |
|
| 2011 |
Ojo J, De Silva S, Han E, Lin P, Wakabayashi M, Nelson R, Lai LL. Krukenberg Tumors from Colorectal Cancer: Presentation, Treatment and Outcomes The American Surgeon. 77: 1381-1385. DOI: 10.1177/000313481107701025 |
0.103 |
|
| 2016 |
Han E, Dellinger T, Wen W, Wu J, Jove R, Horne D, Yim J. Therapeutic potential of ruxolitinib in human ovarian cancer Gynecologic Oncology. 141: 45-46. DOI: 10.1016/J.YGYNO.2016.04.139 |
0.102 |
|
| 2020 |
Wang EW, Wei CH, Liu S, Lee SJ, Shehayeb S, Glaser S, Li R, Saadat S, Shen J, Dellinger T, Han ES, Stewart D, Wilczynski S, Cristea M, Rodriguez-Rodriguez L. Frontline Management of Epithelial Ovarian Cancer-Combining Clinical Expertise with Community Practice Collaboration and Cutting-Edge Research. Journal of Clinical Medicine. 9. PMID 32882942 DOI: 10.3390/jcm9092830 |
0.101 |
|
| 2014 |
Cristea MC, Rivkin S, Lim D, Chung V, Chao J, Wakabayashi M, Paz B, Han E, Lin P, Leong L, Hakim A, Frankel P, Synold T, Carroll M, Openshaw H, et al. 477PPHASE I TRIAL OF INTRAPERITONEAL NAB-PACLITAXEL IN THE TREATMENT OF ADVANCED MALIGNANCIES PRIMARILY CONFINED TO THE PERITONEAL CAVITY. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv159. PMID 28170794 DOI: 10.1093/Annonc/Mdu331.37 |
0.1 |
|
| 2022 |
Dellinger TH, Han ES, Raoof M, Lee B, Wu X, Cho H, He TF, Lee P, Razavi M, Liang WS, Schmolze D, Priceman SJ, Lee S, Lin WC, Lin JF, et al. Hyperthermic Intraperitoneal Chemotherapy-Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer. Jco Precision Oncology. 6: e2100239. PMID 35357903 DOI: 10.1200/PO.21.00239 |
0.098 |
|
| 2023 |
Adamson AW, Ding YC, Steele L, Leong LA, Morgan R, Wakabayashi MT, Han ES, Dellinger TH, Lin PS, Hakim AA, Wilczynski S, Warden CD, Tao S, Bedell V, Cristea MC, et al. Genomic Analyses of Germline and Somatic Variation in High-Grade Serous Ovarian Cancer. Research Square. PMID 36865331 DOI: 10.21203/rs.3.rs-2592107/v1 |
0.098 |
|
| 2011 |
Chase D, Sill M, Chambers M, Darcy K, Han E, Fruehauf J, Monk B, Buening B, Sorosky J, Burger R. Changes in tumor blood flow as estimated by dynamic-contrast MRI may predict activity of single-agent bevacizumab in recurrent epithelial ovarian cancer and primary peritoneal cancer: An exploratory analysis of a Gynecologic Oncology Group phase II trial Gynecologic Oncology. 120: S65-S66. DOI: 10.1016/J.Ygyno.2010.12.157 |
0.095 |
|
| 2018 |
Shinde A, Li R, Chen Y, Amini A, Dellinger T, Lee S, Han E, Wakabayashi M, Nelson R, Beriwal S, Glaser S. Improved Survival with Adjuvant Brachytherapy in Stage Ia Endometrial Cancer of Unfavorable Histology Brachytherapy. 17: S107-S108. DOI: 10.1016/j.brachy.2018.04.196 |
0.095 |
|
| 2019 |
Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Clark R, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, ... ... Han E, et al. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 17: 64-84. PMID 30659131 DOI: 10.6004/Jnccn.2019.0001 |
0.094 |
|
| 2020 |
Haber T, Cornejo YR, Aramburo S, Flores L, Cao P, Liu A, Mooney R, Gilchrist M, Tirughana R, Nwokafor U, Abidi W, Han E, Dellinger T, Wakabayashi MT, Aboody KS, et al. Specific targeting of ovarian tumor-associated macrophages by large, anionic nanoparticles. Proceedings of the National Academy of Sciences of the United States of America. PMID 32732430 DOI: 10.1073/Pnas.1917424117 |
0.09 |
|
| 2015 |
Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dizon DS, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, ... ... Han E, et al. Uterine Sarcoma, Version 1.2016. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 1321-31. PMID 26553763 DOI: 10.6004/Jnccn.2015.0162 |
0.09 |
|
| 2007 |
Han ES, Monk BJ. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecologic Oncology. 105: 3-6. PMID 17383545 DOI: 10.1016/j.ygyno.2007.01.038 |
0.084 |
|
| 2021 |
Abu-Rustum NR, Yashar CM, Bradley K, Campos SM, Chino J, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Diver E, Fisher CM, Frederick P, Gaffney DK, George S, ... ... Han E, et al. NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021. Journal of the National Comprehensive Cancer Network : Jnccn. 19: 888-895. PMID 34416706 DOI: 10.6004/jnccn.2021.0038 |
0.083 |
|
| 2018 |
Li RJ, Shinde A, Chen Y, Amini A, Lee S, Dellinger T, Han E, Han E, Wakabayashi M, Nelson R, Beriwal S, Glaser SM. Improved Survival with Adjuvant Brachytherapy in Cervical Cancer after Hysterectomy with Positive Surgical Margins Brachytherapy. 17: S15. DOI: 10.1016/j.brachy.2018.04.010 |
0.082 |
|
| 2020 |
Dellinger TH, Wu X, Cho H, Liang WS, Han ES, Wakabayashi MT, Lee S, Lin W, Kebria M, Cristea MC, Ruel N, Stewart DB, Wang EW, Raoof M, Lee B, et al. Whole transcriptome changes correlate to exceptional ovarian cancer responders: A sub-analysis of a HIPEC Phase I trial. Journal of Clinical Oncology. 38: 6060-6060. DOI: 10.1200/Jco.2020.38.15_Suppl.6060 |
0.082 |
|
| 2023 |
Senguttuvan RN, Santiago NL, Han ES, Lee B, Lee S, Lin WC, Kebria M, Hakim A, Lin JF, Wakabayashi MT, Ruel N, Tinsley R, Eng M, Stewart DB, Wang EW, et al. ASO Visual Abstract: Impact of Sodium Thiosulfate on Prevention of Nephrotoxicities in HIPEC: An Ancillary Evaluation of Cisplatin-Induced Toxicities in Ovarian Cancer. Annals of Surgical Oncology. PMID 37843668 DOI: 10.1245/s10434-023-14333-2 |
0.081 |
|
| 2009 |
Lin PS, Wakabayashi MT, Han ES. Role of robotic surgery in endometrial cancer. Current Treatment Options in Oncology. 10: 33-43. PMID 19353274 DOI: 10.1007/s11864-009-0086-4 |
0.081 |
|
| 2011 |
Ojo J, De Silva S, Han E, Lin P, Wakabayashi M, Nelson R, Lai LL. Krukenberg tumors from colorectal cancer: presentation, treatment and outcomes. The American Surgeon. 77: 1381-5. PMID 22127094 |
0.081 |
|
| 2021 |
Shim SH, Chae SH, So KA, Lee SJ, Lee JY, Kim TJ, Han ES, Kang SB. Optimal duration of fertility-sparing hormonal treatment for early-stage endometrioid endometrial cancer. Gynecologic Oncology. PMID 33875233 DOI: 10.1016/j.ygyno.2021.03.032 |
0.081 |
|
| 2019 |
Shinde A, Li R, Amini A, Chen YJ, Cristea M, Wang W, Wakabyashi M, Han E, Yashar C, Albuquerque K, Beriwal S, Glaser S. Role of Locoregional Treatment in Vulvar Cancer With Pelvic Lymph Node Metastases: Time to Reconsider FIGO Staging? Journal of the National Comprehensive Cancer Network : Jnccn. 17: 922-930. PMID 31390593 DOI: 10.6004/jnccn.2019.7288 |
0.079 |
|
| 2022 |
Tanyi JL, Randall LM, Chambers SK, Butler KA, Winer IS, Langstraat CL, Han ES, Vahrmeijer AL, Chon HS, Morgan MA, Powell MA, Tseng JH, Lopez AS, Wenham RM. A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2200291. PMID 36070540 DOI: 10.1200/JCO.22.00291 |
0.079 |
|
| 2013 |
Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, DuPont N, Eifel PJ, Gaffney DK, Giuntoli RL, Han E, Huh WK, et al. Cervical cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 320-43. PMID 23486458 DOI: 10.6004/JNCCN.2013.0043 |
0.079 |
|
| 2020 |
Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Giuntoli R, Han E, et al. NCCN Guidelines Insights: Cervical Cancer, Version 1.2020. Journal of the National Comprehensive Cancer Network : Jnccn. 18: 660-666. PMID 32502976 DOI: 10.6004/jnccn.2020.0027 |
0.078 |
|
| 2023 |
Krouse RS, Anderson GL, Arnold KB, Thomson CA, Nfonsam VN, Al-Kasspooles MF, Walker JL, Sun V, Alvarez Secord A, Han ES, Leon-Takahashi AM, Isla-Ortiz D, Rodgers P, Hendren S, Sanchez Salcedo M, et al. Surgical versus non-surgical management for patients with malignant bowel obstruction (S1316): a pragmatic comparative effectiveness trial. The Lancet. Gastroenterology & Hepatology. PMID 37541263 DOI: 10.1016/S2468-1253(23)00191-7 |
0.077 |
|
| 2023 |
Wei CH, Shehayeb S, Santiago NL, Kruper L, Han E, Wang E, Cristea M, Rodriguez-Rodriguez L, Yost SE, Stewart D. BRCA germline mutations in multiethnic gynecologic patients: A 10-year retrospective analysis from a single cancer institute. Plos One. 18: e0286998. PMID 37310942 DOI: 10.1371/journal.pone.0286998 |
0.075 |
|
| 2018 |
Li R, Shinde A, Chen YJ, Amini A, Lee S, Dellinger T, Han E, Wakabayashi M, Nelson R, Beriwal S, Glaser S. Survival benefit of adjuvant brachytherapy after hysterectomy with positive surgical margins in cervical cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 29890264 DOI: 10.1016/j.ijrobp.2018.05.076 |
0.071 |
|
| 2012 |
Chase DM, Sill MW, Monk BJ, Chambers MD, Darcy KM, Han ES, Buening BJ, Sorosky JI, Fruehauf JP, Burger RA. Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II study. Gynecologic Oncology. 126: 375-80. PMID 22683587 DOI: 10.1016/J.Ygyno.2012.06.002 |
0.071 |
|
| 2019 |
Dellinger T, Lee S, Sun V, Ruel N, Liu X, Lin W, Kebria M, Han E. Quality of life (QoL) in ovarian cancer patients following hyperthermic intraperitoneal chemotherapy (HIPEC) versus intraperitoneal (IP) chemotherapy Gynecologic Oncology. 154: 214. DOI: 10.1016/J.YGYNO.2019.04.496 |
0.071 |
|
| 2019 |
Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, ... Han E, et al. Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 17: 1374-1391. PMID 31693991 DOI: 10.6004/Jnccn.2019.0053 |
0.07 |
|
| 2019 |
Li R, Shinde A, Han E, Lee S, Beriwal S, Harkenrider M, Kamrava M, Chen Y, Amini A, Glaser S. Definition of a unified risk classification system for adjuvant therapy in stage I endometrial cancer Gynecologic Oncology. 154: 184. DOI: 10.1016/J.YGYNO.2019.04.429 |
0.067 |
|
| 2018 |
Eng OS, Raoof M, Blakely AM, Yu X, Lee SJ, Han ES, Wakabayashi MT, Yuh B, Lee B, Dellinger TH. A collaborative surgical approach to upper and lower abdominal cytoreductive surgery in ovarian cancer. Journal of Surgical Oncology. PMID 29878375 DOI: 10.1002/jso.25120 |
0.067 |
|
| 2018 |
Glaser S, Li R, Shinde A, Kalash R, Cristea M, Wang E, Han E, Lee S, Dellinger T, Wakabayashi M, Nelson R, Chen Y, Beriwal S, Amini A. Positive Lymph Node Ratio and Number in Endometrial Cancer: A Better Predictor for Survival and Treatment Effect than FIGO Staging? International Journal of Radiation Oncology*Biology*Physics. 102: e647. DOI: 10.1016/j.ijrobp.2018.07.1759 |
0.066 |
|
| 2017 |
Dumitra S, O'Leary M, Raoof M, Wakabayashi M, Dellinger TH, Han ES, Lee SJ, Lee B. The Comprehensive Complication Index: a New Measure of the Burden of Complications After Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology. PMID 29260417 DOI: 10.1245/s10434-017-6157-z |
0.064 |
|
| 2018 |
Chung CP, Dao NT, Wakabayashi MT, Dellinger TH, Lee SJ, Han ES. Concurrent pelvic reconstruction and minimally invasive pelvic cancer surgery. International Urogynecology Journal. PMID 30121701 DOI: 10.1007/s00192-018-3751-y |
0.063 |
|
| 2023 |
Reb AM, Economou D, Cope DG, Borneman T, Tejada MS, Han ES, Cristea M, Ferrell BR. Care Processes and Quality-of-Life Outcomes Affecting the Gynecologic Cancer Survivorship Experience. Oncology Nursing Forum. 50: 185-200. PMID 37677803 DOI: 10.1188/23.ONF.185-200 |
0.063 |
|
| 2021 |
Dellinger TH, Han ES. State of the Science: The role of HIPEC in the treatment of ovarian cancer. Gynecologic Oncology. 160: 364-368. PMID 33419611 DOI: 10.1016/j.ygyno.2020.12.029 |
0.062 |
|
| 2017 |
Chung CP, Cao S, Wakabayashi G, Han ES. Management of pelvic floor disorder in a diethylstilbestrol daughter. Proceedings (Baylor University. Medical Center). 30: 291-292. PMID 28670059 |
0.055 |
|
| 2021 |
Ladbury C, Li R, Shiao J, Liu J, Cristea M, Han E, Dellinger T, Lee S, Wang E, Fisher C, Chen YJ, Amini A, Robin T, Glaser S. Characterizing impact of positive lymph node number in endometrial cancer using machine-learning: A better prognostic indicator than FIGO staging? Gynecologic Oncology. PMID 34794840 DOI: 10.1016/j.ygyno.2021.11.007 |
0.052 |
|
| 2019 |
Li R, Shinde A, Han E, Lee S, Beriwal S, Harkenrider M, Kamrava M, Chen YJ, Glaser S. A proposal for a new classification of "unfavorable risk criteria" in patients with stage I endometrial cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 29: 1086-1093. PMID 31474587 DOI: 10.1136/ijgc-2019-000264 |
0.051 |
|
| 2015 |
Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, et al. Cervical cancer, version 2.2015: Featured updates to the NCCN guidelines featured updates to the NCCN guidelines Jnccn Journal of the National Comprehensive Cancer Network. 13: 395-404. |
0.048 |
|
| 2004 |
Luo D, Han E, Belcheva N, Saltzman WM. A self-assembled, modular DNA delivery system mediated by silica nanoparticles. Journal of Controlled Release : Official Journal of the Controlled Release Society. 95: 333-41. PMID 14980781 DOI: 10.1016/J.Jconrel.2003.11.019 |
0.047 |
|
| 2019 |
Cristea MC, Frankel P, Synold T, Rivkin S, Lim D, Chung V, Chao J, Wakabayashi M, Paz B, Han E, Lin P, Leong L, Hakim A, Carroll M, Prakash N, et al. A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Cancer Chemotherapy and Pharmacology. PMID 30623229 DOI: 10.1007/S00280-019-03767-9 |
0.046 |
|
| 2020 |
Chung CP, Edrosa E, Wakabayashi MT, Dellinger TH, Lee SJ, Chan K, Han ES. Prolapse repair after anterior exenteration. International Urogynecology Journal. PMID 32737535 DOI: 10.1007/s00192-020-04465-4 |
0.042 |
|
| 2017 |
Eng OS, Dumitra S, O'Leary M, Raoof M, Wakabayashi M, Dellinger TH, Han ES, Lee SJ, Paz IB, Lee B. Association of Fluid Administration With Morbidity in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy. Jama Surgery. PMID 28832866 DOI: 10.1001/jamasurg.2017.2865 |
0.041 |
|
| 2020 |
Banapour P, Yuh B, Chenam A, Shen JK, Ruel N, Han ES, Kim JY, Maghami EG, Pigazzi A, Raz DJ, Singh GP, Wakabayashi M, Woo Y, Fong Y, Lau CS. Readmission and complications after robotic surgery: experience of 10,000 operations at a comprehensive cancer center. Journal of Robotic Surgery. PMID 32277400 DOI: 10.1007/s11701-020-01077-4 |
0.039 |
|
| 2017 |
Eng OS, Dumitra S, O'Leary M, Wakabayashi M, Dellinger TH, Han ES, Lee SJ, Benjamin Paz I, Singh G, Lee B. Base Excess as a Predictor of Complications in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology. PMID 28560593 DOI: 10.1245/s10434-017-5869-4 |
0.038 |
|
| 2016 |
Raoof M, Yuan Y, Wen W, Yan J, Xing Q, Han E, Yim JH. Inhibition of the PI3K Pathway by T-DM1 and its Maytansinoid-Conjugate Journal of the American College of Surgeons. 223: e3. DOI: 10.1016/J.JAMCOLLSURG.2016.08.011 |
0.035 |
|
| 2022 |
Kohut A, Whitaker T, Walter L, Li SY, Han E, Lee S, Wakabayashi MT, Dellinger TH, Han ES, Rodriguez-Rodriguez L, Chung C. Feasibility of combining pelvic reconstruction with gynecologic oncology-related surgery. International Urogynecology Journal. PMID 35501570 DOI: 10.1007/s00192-022-05212-7 |
0.026 |
|
| 2007 |
Sinsakul M, Sika M, Rodby R, Middleton J, Shyr Y, Chen H, Han E, Lehrich R, Clyne S, Schulman G, Harris R, Lewis J. A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 50: 946-51. PMID 18037095 DOI: 10.1053/j.ajkd.2007.09.005 |
0.023 |
|
| 2015 |
Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Cho KR, Chu C, Cohn D, Crispens MA, Dizon DS, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, ... ... Han E, et al. Uterine sarcoma, version 1.2016: Featured updates to the NCCN Guidelines Jnccn Journal of the National Comprehensive Cancer Network. 13: 1321-1331. |
0.015 |
|
| 2016 |
Dellinger TH, Wakabayashi MT, Han ES. Comprehensive staging of uterine carcinosarcoma utilizing a multiquadrant robotic platform. Journal of Minimally Invasive Gynecology. PMID 27794476 DOI: 10.1016/j.jmig.2016.10.010 |
0.01 |
|
| Hide low-probability matches. |